Literature DB >> 33560388

Pembrolizumab in mycosis fungoides with PD-L1 structural variants.

Sara Beygi1, Sebastian Fernandez-Pol2, George Duran1, Erica B Wang3, Henning Stehr2, James L Zehnder2, Nirasha Ramchurren4, Steven P Fling4, Martin A Cheever4, Wen-Kai Weng3,5, Youn H Kim1,3, Michael S Khodadoust1,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33560388      PMCID： PMC7876893          DOI： 10.1182/bloodadvances.2020002371

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  19 in total

1.  Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.

Authors:  Michael S Khodadoust; Alain H Rook; Pierluigi Porcu; Francine Foss; Alison J Moskowitz; Andrei Shustov; Satish Shanbhag; Lubomir Sokol; Steven P Fling; Nirasha Ramchurren; Robert Pierce; Asa Davis; Richard Shine; Shufeng Li; Sophia Fong; Jinah Kim; Yi Yang; Wendy M Blumenschein; Jennifer H Yearley; Biswajit Das; Rajesh Patidar; Vivekananda Datta; Erin Cantu; Justine N McCutcheon; Chris Karlovich; P Mickey Williams; Priyanka B Subrahmanyam; Holden T Maecker; Steven M Horwitz; Elad Sharon; Holbrook E Kohrt; Martin A Cheever; Youn H Kim
Journal:  J Clin Oncol       Date:  2019-09-18       Impact factor: 44.544

2.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

3.  Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.

Authors:  Steven M Horwitz; Youn H Kim; Francine Foss; Jasmine M Zain; Patricia L Myskowski; Mary Jo Lechowicz; David C Fisher; Andrei R Shustov; Nancy L Bartlett; Maria L Delioukina; Tony Koutsoukos; Michael E Saunders; Owen A O'Connor; Madeleine Duvic
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

4.  Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

Authors:  Elise A Olsen; Youn H Kim; Timothy M Kuzel; Theresa R Pacheco; Francine M Foss; Sareeta Parker; Stanley R Frankel; Cong Chen; Justin L Ricker; Jean Marie Arduino; Madeleine Duvic
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

5.  Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Authors:  Alexander M Lesokhin; Stephen M Ansell; Philippe Armand; Emma C Scott; Ahmad Halwani; Martin Gutierrez; Michael M Millenson; Adam D Cohen; Stephen J Schuster; Daniel Lebovic; Madhav Dhodapkar; David Avigan; Bjoern Chapuy; Azra H Ligon; Gordon J Freeman; Scott J Rodig; Deepika Cattry; Lili Zhu; Joseph F Grosso; M Brigid Bradley Garelik; Margaret A Shipp; Ivan Borrello; John Timmerman
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

6.  Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.

Authors:  Keisuke Kataoka; Yuichi Shiraishi; Yohei Takeda; Seiji Sakata; Misako Matsumoto; Seiji Nagano; Takuya Maeda; Yasunobu Nagata; Akira Kitanaka; Seiya Mizuno; Hiroko Tanaka; Kenichi Chiba; Satoshi Ito; Yosaku Watatani; Nobuyuki Kakiuchi; Hiromichi Suzuki; Tetsuichi Yoshizato; Kenichi Yoshida; Masashi Sanada; Hidehiro Itonaga; Yoshitaka Imaizumi; Yasushi Totoki; Wataru Munakata; Hiromi Nakamura; Natsuko Hama; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Takuro Kameda; Kyoko Masuda; Nagahiro Minato; Koichi Kashiwase; Koji Izutsu; Akifumi Takaori-Kondo; Yasushi Miyazaki; Satoru Takahashi; Tatsuhiro Shibata; Hiroshi Kawamoto; Yoshiki Akatsuka; Kazuya Shimoda; Kengo Takeuchi; Tsukasa Seya; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2016-05-23       Impact factor: 49.962

7.  Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Authors:  Youn H Kim; Martine Bagot; Lauren Pinter-Brown; Alain H Rook; Pierluigi Porcu; Steven M Horwitz; Sean Whittaker; Yoshiki Tokura; Maarten Vermeer; Pier Luigi Zinzani; Lubomir Sokol; Stephen Morris; Ellen J Kim; Pablo L Ortiz-Romero; Herbert Eradat; Julia Scarisbrick; Athanasios Tsianakas; Craig Elmets; Stephane Dalle; David C Fisher; Ahmad Halwani; Brian Poligone; John Greer; Maria Teresa Fierro; Amit Khot; Alison J Moskowitz; Amy Musiek; Andrei Shustov; Barbara Pro; Larisa J Geskin; Karen Dwyer; Junji Moriya; Mollie Leoni; Jeffrey S Humphrey; Stacie Hudgens; Dmitri O Grebennik; Kensei Tobinai; Madeleine Duvic
Journal:  Lancet Oncol       Date:  2018-08-09       Impact factor: 41.316

8.  Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes.

Authors:  Linghua Wang; Xiao Ni; Kyle R Covington; Betty Y Yang; Jessica Shiu; Xiang Zhang; Liu Xi; Qingchang Meng; Timothy Langridge; Jennifer Drummond; Lawrence A Donehower; Harshavardhan Doddapaneni; Donna M Muzny; Richard A Gibbs; David A Wheeler; Madeleine Duvic
Journal:  Nat Genet       Date:  2015-11-09       Impact factor: 38.330

9.  Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in Sézary syndrome.

Authors:  Mark J Kiel; Anagh A Sahasrabuddhe; Delphine C M Rolland; Thirunavukkarasu Velusamy; Fuzon Chung; Matthew Schaller; Nathanael G Bailey; Bryan L Betz; Roberto N Miranda; Pierluigi Porcu; John C Byrd; L Jeffrey Medeiros; Steven L Kunkel; David W Bahler; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Nat Commun       Date:  2015-09-29       Impact factor: 14.919

10.  The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.

Authors:  Yongfeng Wu; Jinming Xu; Chengli Du; Yihua Wu; Dajing Xia; Wang Lv; Jian Hu
Journal:  Front Oncol       Date:  2019-11-05       Impact factor: 6.244
View more
  4 in total

1.  What factors guide treatment selection in mycosis fungoides and Sezary syndrome?

Authors:  Youn H Kim
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Cutaneous T cell lymphoma.

Authors:  Reinhard Dummer; Maarten H Vermeer; Julia J Scarisbrick; Youn H Kim; Connor Stonesifer; Cornelis P Tensen; Larisa J Geskin; Pietro Quaglino; Egle Ramelyte
Journal:  Nat Rev Dis Primers       Date:  2021-08-26       Impact factor: 52.329

3.  Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma.

Authors:  Sara Beygi; George E Duran; Sebastian Fernandez-Pol; Alain H Rook; Youn H Kim; Michael S Khodadoust
Journal:  Blood       Date:  2022-06-30       Impact factor: 25.476

4.  Single-cell RNA-sequencing reveals predictive features of response to pembrolizumab in Sézary syndrome.

Authors:  Tianying Su; George E Duran; Alexa C Kwang; Nirasha Ramchurren; Steven P Fling; Youn H Kim; Michael S Khodadoust
Journal:  Oncoimmunology       Date:  2022-08-27       Impact factor: 7.723
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.